← Leaderboards
Andrew A Lane
Dana-Farber Cancer Inst
$4,246,865
Attributed
$5,115,316
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,115,316 · 4
By mechanism
R37$2,963,904 · 1
U01$1,302,677 · 1
K08$752,490 · 1
P30$96,245 · 1
Top collaborators
- Michael Hemann2 shared
- Scott R Manalis2 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- David Marc Weinstock$10,844,261
- David S Pellman$18,057,380
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsInnovationCellsRelapseMutationGeneticTherapeutic TargetHematopoiesisCell TransformationGenesBiologyPhenotypeBone MarrowIn VivoComplexCancer BiologyAreaMalignant - DescriptorClinical TrialsChemotherapyMissionDendritic CellsLaboratoriesPathogenesis
Grant awards (17)
Targeting minimal residual disease in AML by using single-cell morphological and biophysical analysis with deep learning$655,219
U01 · FY2025 · CA
Program 04 Leukemia$55,127
P30 · FY2025 · CA · contact PI
Targeting minimal residual disease in AML by using single-cell morphological and biophysical analysis with deep learning$647,458
U01 · FY2024 · CA
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)$377,137
R37 · FY2024 · CA · contact PI
Program 04 Leukemia$41,118
P30 · FY2024 · CA · contact PI
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)$392,412
R37 · FY2023 · CA · contact PI
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)$396,986
R37 · FY2022 · CA · contact PI
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)$396,986
R37 · FY2021 · CA · contact PI
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)$174,100
R37 · FY2021 · CA · contact PI
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)$444,222
R37 · FY2020 · CA · contact PI
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)$385,075
R37 · FY2019 · CA · contact PI
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)$396,986
R37 · FY2018 · CA · contact PI
Targeting Chromatin Modifications in Leukemia with Trisomy 21$128,526
K08 · FY2018 · CA · contact PI
Targeting Chromatin Modifications in Leukemia with Trisomy 21$155,991
K08 · FY2017 · CA · contact PI
Targeting Chromatin Modifications in Leukemia with Trisomy 21$155,991
K08 · FY2016 · CA · contact PI
Targeting Chromatin Modifications in Leukemia with Trisomy 21$155,991
K08 · FY2015 · CA · contact PI
Targeting Chromatin Modifications in Leukemia with Trisomy 21$155,991
K08 · FY2014 · CA · contact PI